ACLX-001
Relapsed/Refractory Multiple Myeloma
Phase 1Active
Key Facts
About Arcellx
Arcellx is a mission-driven biotech founded in 2014 to advance humanity by engineering safer, more effective, and broadly accessible cell therapies. Its primary achievement is the development of a novel, fully synthetic D-Domain technology, which underpins its two therapeutic platforms: the single-infusion ddCAR and the dosable, controllable ARC-SparX system. The company's strategy leverages high-value partnerships, most notably a global collaboration with Kite Pharma, to accelerate the development and commercialization of its lead candidate, anito-cel, for relapsed/refractory multiple myeloma, while advancing a broader pipeline in hematologic malignancies, solid tumors, and autoimmune conditions.
View full company profileTherapeutic Areas
Other Relapsed/Refractory Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| Aplidin (plitidepsin) | PharmaMar | Approved (Conditional - AU) |
| CAR T-Cell Therapy Program | Dr. Reddy's Laboratories | Development |
| inobrodib + Pd (InoPd) | CellCentric | Phase 1/2 |
| TECVAYLI + DARZALEX FASPRO | Johnson and Johnson Innovative Medicine | Approved |
| HDP-101 | Heidelberg Pharma | Phase 1/2a |
| CT053 | CARsgen Therapeutics | Phase 1b/2 |
| P-BCMA-ALLO1 | Poseida Therapeutics | Phase 1 |
| ABBV-383 | AbbVie | Phase 1 |
| Blenrep (belantamab mafodotin) | GSK plc | Phase III |
| bri-cel (BAY 2413334) | Bayer | Phase I |
| Ciltacabtagene autoleucel (Carvykti) | Genscript Biotech | Approved / Phase 3 |
| CAR-T Cell Therapy | Dr. Reddy's Laboratories | Discovery/Development |